2 results
Approved WMOCompleted
To investigate trastuzmab-paclitaxel in EGFR-mutated NSCLC patients who have overexpression of HER2 and who have progressed on standard TKI-treatment
Approved WMOCompleted
The primary objective of this study is to evaluate efficacy and safety. Secondary objectives: PK, PK-PD.